Challes Les Eaux

This trial focuses on people who have had surgery to repair a torn anterior cruciate ligament ACL, a common knee injury often caused by sports. Researchers are studying whether a personalized and optimized rehabilitation program guided by monthly assessments from physiotherapists during the 3 to 6 months after surgery can reduce the risk of new ACL injuries compared to standard rehabilitation. This phase is critical because the return to running and gradual resumption of sports vary greatly between patients, and there is no current consensus on objective criteria for this stage of recovery. The study compares two rehabilitation approaches. One group receives the usual rehabilitation following French national guidelines, with an evaluation at 6 months to decide if return to sport is allowed. The other group gets the usual rehabilitation plus expert physiotherapists perform monthly clinical and functional assessments from 3 to 6 months, providing personalized exercise and running recommendations to the treating physiotherapist. This optimized rehabilitation aims to better prepare patients for returning to their favorite sports activities. Participants will be monitored up to 24 months after surgery. Researchers will assess the number of patients who experience at least one new ACL injury, check who meets the criteria to return to sports at 6 months, record any post-surgical complications, and measure running biomechanical symmetry. These evaluations include clinical tests and functional assessments to track progress and safety. The study runs until December 2029 and involves young adults aged 18 to 25 who play competitive pivoting or contact sports.

Researchers are conducting a French non-interventional longitudinal multicenter cohort study to evaluate the added value of olaparib for treating patients with metastatic castration-resistant prostate cancer mCRPC in real-world settings. The study aims to assess treatment sequencing, effectiveness, safety, and BRCA testing patterns, helping to inform future clinical practice. This observational study is sponsored by AstraZeneca. The study observes adult male patients who have started olaparib treatment within at least the last two months or who participated in a funded early access program. There are no assigned treatment groups or interventions beyond olaparib use as decided by their physician. Data collection continues up to 32 months to capture treatment patterns and patient characteristics. Participants data on treatment duration, disease progression, therapy sequences, symptomatic skeletal events, and BRCA testing timing will be collected and analyzed up to 24 months from olaparib initiation. Socio-demographic and clinical characteristics of patients and physicians will be gathered at the end of enrollment. The study monitors reasons for dose changes, interruptions, and treatment cessation, ensuring comprehensive real-world evidence about olaparib in mCRPC patients.